

# News Releases

Register for email alerts.

All Categories

Archive



Date	12/15/14
Title	Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance
Download	<a href="#">PDF</a>

Date	11/28/14
Title	Valeant Announces Redemption of US\$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018
Download	<a href="#">PDF</a>

Date	11/25/14
Title	Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris
Download	<a href="#">PDF</a>

Date	11/20/14
Title	Valeant Pharmaceuticals Announces New \$2 Billion Securities Repurchase Program
Download	<a href="#">PDF</a>

Date	11/17/14
------	----------

**Title**

Valeant Comments On Allergan Announcement

**Download**[PDF](#)**Date**

11/13/14

**Title**

Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey

**Download**[PDF](#)**Date**

11/07/14

**Title**

Valeant Pharmaceuticals Sends Letter To Physician Customers

**Download**[PDF](#)**Date**

11/04/14

**Title**

Valeant And Pershing Square May Vote At Special Meeting

**Download**[PDF](#)**Date**

10/27/14

**Title**

Valeant Delivers Letter To Allergan Board

**Download**[PDF](#)**Date**

10/20/14

**Title**

Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results

**Download**[PDF](#)**Date**

10/15/14

**Title**

Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014

**Download**

**PDF**

**Date** 09/30/14

**Title**

Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA

**Download**

**PDF**

**Date** 09/26/14

**Title**

Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38%

**Download**

**PDF**

**Date** 09/25/14

**Title**

Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals

**Download**

**PDF**

**Date** 09/25/14

**Title**

Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies

**Download**

**PDF**

**Date** 09/24/14

**Title**

Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director

**Download**

**PDF**

**Date** 09/15/14

**Title**

Valeant Announces Redemption of All of the Outstanding \$500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017

**Download**

**PDF**

**Date**

09/08/14

**Title**

Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester

**Download**

**PDF**

**Date**

08/15/14

**Title**

Valeant Extends Offer To Acquire Allergan

**Download**

**PDF**

**Date**

08/11/14

**Title**

Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino

**Download**

**PDF**

**Date**

08/06/14

**Title**

Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders

**Download**

**PDF**

**Date**

08/01/14

**Title**

Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit

**Download**

**PDF**

**Date**

07/31/14

**Title**

Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results

**Download**

**PDF**

<b>Date</b>	07/31/14
<b>Title</b> Results (pdf version)	Valeant Pharmaceuticals Reports Second Quarter 2014 Financial
<b>Download</b>	<a href="#">PDF</a>

---

<b>Date</b>	07/24/14
<b>Title</b> Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements	
<b>Download</b>	<a href="#">PDF</a>

---

<b>Date</b>	07/21/14
<b>Title</b> Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements	
<b>Download</b>	<a href="#">PDF</a>

---

<b>Date</b>	07/18/14
<b>Title</b> Valeant Pharmaceuticals Files Investor Presentation	
<b>Download</b>	<a href="#">PDF</a>

---

<b>Date</b>	07/17/14
<b>Title</b> Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure	
<b>Download</b>	<a href="#">PDF</a>

---

<b>Date</b>	07/14/14
<b>Title</b> Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan	
<b>Download</b>	<a href="#">PDF</a>

---

<b>Date</b>	07/10/14
-------------	----------

**Title**

Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma

**Download**[PDF](#)**Date**

07/08/14

**Title**

Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology

**Download**[PDF](#)**Date**

06/25/14

**Title**

Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan

**Download**[PDF](#)**Date**

06/23/14

**Title**

Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements

**Download**[PDF](#)**Date**

06/18/14

**Title**

Valeant Commences Exchange Offer For Allergan

**Download**[PDF](#)**Date**

06/16/14

**Title**

Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk

**Download**[PDF](#)**Date**

06/13/14

**Title**

Valeant Pharmaceuticals Announces Planned Management Departure

**Download**

**PDF**

**Date**

06/13/14

**Title**

Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations

**Download**

**PDF**

**Date**

06/09/14

**Title**

Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis

**Download**

**PDF**

**Date**

05/30/14

**Title**

Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations

**Download**

**PDF**

**Date**

05/28/14

**Title**

Valeant Substantially Increases Merger Proposal For Allergan

**Download**

**PDF**

**Date**

05/28/14

**Title**

Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For \$1.4 Billion

**Download**

**PDF**

**Date**

05/27/14

**Title**

Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET

**Download**

**PDF**

**Date** 05/23/14

**Title**

Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014

**Download**

[PDF](#)

**Date** 05/21/14

**Title**

Valeant Pharmaceuticals Announces 2014 Annual Meeting Results

**Download**

[PDF](#)

**Date** 05/20/14

**Title**

Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET

**Download**

[PDF](#)

**Date** 05/13/14

**Title**

Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal

**Download**

[PDF](#)

**Date** 05/12/14

**Title**

Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis

**Download**

[PDF](#)

**Date** 05/08/14

**Title**

Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results

**Download**

[PDF](#)

**Date** 05/01/14



**Title**

Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders

**Download**

**PDF**

**Date**

04/24/14

**Title**

Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available

**Download**

**PDF**

**Date**

04/24/14

**Title**

Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014

**Download**

**PDF**

**Date**

04/23/14

**Title**

Valeant Pharmaceuticals Announces Nominations For Board Of Directors

**Download**

**PDF**

**Date**

04/22/14

**Title**

Valeant Proposes to Combine With Allergan for \$48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share

**Download**

**PDF**

**Date**

03/25/14

**Title**

Actavis and Valeant Announce FDA Approval for Metronidazole 1.3%

**Download**

**PDF**

**Date**

02/27/14

**Title**

Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results

**Download**

**PDF**

**Date**

02/05/14

**Title**

Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014

**Download**

**PDF**

**Date**

02/03/14

**Title**

Valeant Pharmaceuticals to Acquire Precision Dermatology for \$475 Million

**Download**

**PDF**

**Date**

01/31/14

**Title**

Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08%

**Download**

**PDF**

**Date**

01/23/14

**Title**

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc.

**Download**

**PDF**

**Date**

01/23/14

**Title**

Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc.

**Download**

**PDF**

**Date**

01/22/14

**Title**

Valeant Pharmaceuticals Announces New \$1.5 Billion Securities Repurchase Program

**Download**

**PDF**

**Date**

01/15/14



Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)  
877-281-6642  
514-856-3855 (Canada)

Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)  
908-569-3692

LEGAL NOTICE      PRIVACY POLICY

EMAIL ALERTS      EMAIL PAGE      RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.  
©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION